Brepocitinib is an oral medication being studied for its effectiveness and safety in treating adults with active, non-infectious uveitis. Uveitis is an inflammation of the middle layer of the eye, and this study focuses on intermediate, posterior, and panuveitis types. The goal is to see how well brepocitinib can reduce inflammation and improve symptoms in these patients.

Non-infectious Intermediate Uveitis – This is an inflammation of the middle layer of the eye, specifically affecting the area between the iris and the choroid. It can cause symptoms such as blurred vision, floaters, and eye pain. The inflammation can lead to complications like cataracts or glaucoma if not managed. The condition can be chronic, with periods of flare-ups and remissions.

Non-infectious Posterior Uveitis – This form of uveitis affects the back part of the eye, including the retina and choroid. It can result in symptoms like vision loss, floaters, and eye redness. The inflammation can cause damage to the retina, potentially leading to vision impairment. It often requires careful monitoring due to its potential impact on vision.

Non-infectious Panuveitis – This is a type of uveitis where inflammation occurs throughout the entire uveal tract, affecting the front, middle, and back of the eye. Symptoms may include eye pain, redness, blurred vision, and sensitivity to light. The widespread inflammation can lead to complications affecting the entire eye structure. It is a complex condition that can vary in severity and duration.